{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:38:39Z","timestamp":1778866719740,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011421","name":"Sanofi China Investment\u00a0Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s12325-018-0841-7","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T11:10:55Z","timestamp":1543835455000},"page":"131-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study"],"prefix":"10.1007","volume":"36","author":[{"given":"Hui","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiding","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiqun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-8715","authenticated-orcid":false,"given":"Shui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"841_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12682","author":"LW Chow","year":"2017","unstructured":"Chow LW, Biganzoli L, Leo AD, et al. Toxicity profile differences of adjuvant docetaxel\/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. Asia Pac J Clin Oncol. 2017. \n                    https:\/\/doi.org\/10.1111\/ajco.12682\n                    \n                  .","journal-title":"Asia Pac J Clin Oncol"},{"key":"841_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1471-2407-11-364","volume":"11","author":"J Li","year":"2011","unstructured":"Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year (1999\u20132008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer. 2011;11:364. \n                    https:\/\/doi.org\/10.1186\/1471-2407-11-364\n                    \n                  .","journal-title":"BMC Cancer."},{"key":"841_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-015-0439-8","volume":"13","author":"J Anampa","year":"2015","unstructured":"Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015;13:195. \n                    https:\/\/doi.org\/10.1186\/s12916-015-0439-8\n                    \n                  .","journal-title":"BMC Med."},{"issue":"Suppl 5","key":"841_CR4","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8\u201330. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv298\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"4","key":"841_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","volume":"15","author":"WJ Gradishar","year":"2017","unstructured":"Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Cancer Netw. 2017;15(4):433\u201351.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"841_CR6","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/jop.2016.011205","volume":"12","author":"NL Henry","year":"2016","unstructured":"Henry NL, Somerfield MR, Krop IE. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American society of clinical oncology endorsement of cancer care ontario guideline recommendations summary. J Oncol Pract. 2016;12(5):482\u20134. \n                    https:\/\/doi.org\/10.1200\/jop.2016.011205\n                    \n                  .","journal-title":"J Oncol Pract."},{"issue":"20","key":"841_CR7","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/jco.2016.67.0182","volume":"34","author":"N Denduluri","year":"2016","unstructured":"Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American society of clinical oncology guideline adaptation of the cancer care ontario clinical practice guideline. J Clin Oncol. 2016;34(20):2416\u201327. \n                    https:\/\/doi.org\/10.1200\/jco.2016.67.0182\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"9814","key":"841_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/s0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (London, England). 2012;379(9814):432\u201344. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(11)61625-5\n                    \n                  .","journal-title":"Lancet (London, England)."},{"key":"841_CR9","doi-asserted-by":"publisher","unstructured":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England). 2005;365(9472):1687\u2013717. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(05)66544-0\n                    \n                  .","DOI":"10.1016\/s0140-6736(05)66544-0"},{"key":"841_CR10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16439","author":"Q Li","year":"2017","unstructured":"Li Q, Yang Z, Fan J, et al. A nation-wide multicenter 10-year (1999\u20132008) retrospective study of chemotherapy in Chinese breast cancer patients. Oncotarget. 2017. \n                    https:\/\/doi.org\/10.18632\/oncotarget.16439\n                    \n                  .","journal-title":"Oncotarget"},{"issue":"3","key":"841_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.5306\/wjco.v5.i3.529","volume":"5","author":"JA Crozier","year":"2014","unstructured":"Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: to use or not to use, the anthracyclines. World J Clin Oncol. 2014;5(3):529\u201338. \n                    https:\/\/doi.org\/10.5306\/wjco.v5.i3.529\n                    \n                  .","journal-title":"World J Clin Oncol"},{"issue":"18","key":"841_CR12","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/jco.2011.40.1273","volume":"30","author":"SH Giordano","year":"2012","unstructured":"Giordano SH, Lin Y-L, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30(18):2232\u20139. \n                    https:\/\/doi.org\/10.1200\/jco.2011.40.1273\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"3","key":"841_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/1078155214531513","volume":"21","author":"J Greene","year":"2015","unstructured":"Greene J, Hennessy B. The role of anthracyclines in the treatment of early breast cancer. J Oncol Pharm Pract. 2015;21(3):201\u201312. \n                    https:\/\/doi.org\/10.1177\/1078155214531513\n                    \n                  .","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"841_CR14","doi-asserted-by":"publisher","first-page":"e26946","DOI":"10.1371\/journal.pone.0026946","volume":"6","author":"YY Qin","year":"2011","unstructured":"Qin YY, Li H, Guo XJ, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One. 2011;6(11):e26946. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0026946\n                    \n                  .","journal-title":"PLoS One"},{"key":"841_CR15","doi-asserted-by":"publisher","unstructured":"Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007;(4):Cd004421. \n                    https:\/\/doi.org\/10.1002\/14651858.cd004421.pub2\n                    \n                  .","DOI":"10.1002\/14651858.cd004421.pub2"},{"issue":"Suppl 2","key":"841_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1634\/theoncologist.9-suppl_2-24","volume":"9","author":"J Crown","year":"2004","unstructured":"Crown J, O\u2019Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 2004;9(Suppl 2):24\u201332.","journal-title":"Oncologist"},{"issue":"5","key":"841_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/cncr.30421","volume":"123","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Kuranami M, Inoue K, et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 2017;123(5):759\u201368. \n                    https:\/\/doi.org\/10.1002\/cncr.30421\n                    \n                  .","journal-title":"Cancer"},{"issue":"5","key":"841_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155215625459","volume":"22","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, Li X, Woods M, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract. 2016;22(5):702\u201316. \n                    https:\/\/doi.org\/10.1177\/1078155215625459\n                    \n                  .","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"841_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/jco.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178\u201384. \n                    https:\/\/doi.org\/10.1200\/jco.2005.09.102\n                    \n                  .","journal-title":"J Clin Oncol."},{"issue":"3","key":"841_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/nejm199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164\u201370. \n                    https:\/\/doi.org\/10.1056\/nejm199107183250305\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"4","key":"841_CR21","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.3747\/co.19.948","volume":"19","author":"X Zhu","year":"2012","unstructured":"Zhu X, Bouganim N, Vandermeer L, Dent SF, Dranitsaris G, Clemons MJ. Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience. Curr Oncol (Toronto, Ont). 2012;19(4):e239\u201343. \n                    https:\/\/doi.org\/10.3747\/co.19.948\n                    \n                  .","journal-title":"Curr Oncol (Toronto, Ont)."},{"key":"841_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/cmar.s40601","volume":"6","author":"MY Ho","year":"2014","unstructured":"Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014;6:253\u20139. \n                    https:\/\/doi.org\/10.2147\/cmar.s40601\n                    \n                  .","journal-title":"Cancer Manag Res"},{"issue":"8","key":"841_CR23","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/jco.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431\u20139. \n                    https:\/\/doi.org\/10.1200\/jco.2003.09.081\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"10","key":"841_CR24","doi-asserted-by":"publisher","first-page":"e107273","DOI":"10.1371\/journal.pone.0107273","volume":"9","author":"R Yerushalmi","year":"2014","unstructured":"Yerushalmi R, Goldvaser H, Sulkes A, et al. Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 & 12 in breast cancer patients: a retrospective analysis. PLoS One. 2014;9(10):e107273. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0107273\n                    \n                  .","journal-title":"PLoS One"},{"issue":"12","key":"841_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.6004\/jnccn.2015.0176","volume":"13","author":"WJ Gradishar","year":"2015","unstructured":"Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights breast cancer, version 1.2016. J Natl Compr Cancer Netw. 2015;13(12):1475\u201385.","journal-title":"J Natl Compr Cancer Netw."},{"issue":"28","key":"841_CR26","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/jco.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199\u2013212. \n                    https:\/\/doi.org\/10.1200\/jco.2015.62.3488\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"21","key":"841_CR27","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1200\/jco.2008.20.8793","volume":"27","author":"DR Gandara","year":"2009","unstructured":"Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009;27(21):3540\u20136. \n                    https:\/\/doi.org\/10.1200\/jco.2008.20.8793\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"17","key":"841_CR28","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ejca.2011.06.027","volume":"47","author":"HS Han","year":"2011","unstructured":"Han HS, Reis IM, Zhao W, et al. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer (Oxford, England: 1990). 2011;47(17):2537\u201345. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2011.06.027\n                    \n                  .","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"6","key":"841_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/coc.0b013e3181f94716","volume":"34","author":"D Hendler","year":"2011","unstructured":"Hendler D, Rizel S, Yerushalmi R, et al. Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study. Am J Clin Oncol. 2011;34(6):619\u201324. \n                    https:\/\/doi.org\/10.1097\/coc.0b013e3181f94716\n                    \n                  .","journal-title":"Am J Clin Oncol"},{"issue":"28","key":"841_CR30","doi-asserted-by":"publisher","first-page":"6908","DOI":"10.1200\/jco.2005.03.099","volume":"23","author":"P Papaldo","year":"2005","unstructured":"Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol. 2005;23(28):6908\u201318. \n                    https:\/\/doi.org\/10.1200\/jco.2005.03.099\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"16","key":"841_CR31","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/nejmoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663\u201371. \n                    https:\/\/doi.org\/10.1056\/nejmoa0707056\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"8","key":"841_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1200\/jco.2008.18.4028","volume":"27","author":"S Jones","year":"2009","unstructured":"Jones S, Holmes FA, O\u2019Shaughnessy J, et al. Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us Oncology Research Trial 9735. J Clin Oncol. 2009;27(8):1177\u201383. \n                    https:\/\/doi.org\/10.1200\/jco.2008.18.4028\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"2","key":"841_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/jco.2001.19.2.314","volume":"19","author":"JM Nabholtz","year":"2001","unstructured":"Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol. 2001;19(2):314\u201321. \n                    https:\/\/doi.org\/10.1200\/jco.2001.19.2.314\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"6","key":"841_CR34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/jco.2003.04.040","volume":"21","author":"JM Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21(6):968\u201375. \n                    https:\/\/doi.org\/10.1200\/jco.2003.04.040\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"12","key":"841_CR35","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/jco.2000.18.12.2369","volume":"18","author":"JA Sparano","year":"2000","unstructured":"Sparano JA, O\u2019Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol. 2000;18(12):2369\u201377. \n                    https:\/\/doi.org\/10.1200\/jco.2000.18.12.2369\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"1","key":"841_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/s1470-2045(12)70525-9","volume":"14","author":"JR Mackey","year":"2013","unstructured":"Mackey JR, Martin M, Pienkowski T, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013;14(1):72\u201380. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(12)70525-9\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"22","key":"841_CR37","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/nejmoa0909638","volume":"362","author":"SM Swain","year":"2010","unstructured":"Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053\u201365. \n                    https:\/\/doi.org\/10.1056\/nejmoa0909638\n                    \n                  .","journal-title":"N Engl J Med."},{"issue":"6","key":"841_CR38","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/annonc\/mdw098","volume":"27","author":"JR Mackey","year":"2016","unstructured":"Mackey JR, Pienkowski T, Crown J, et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol. 2016;27(6):1041\u20137. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw098\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"2","key":"841_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7314\/APJCP.2016.17.2.697","volume":"17","author":"SB Kim","year":"2016","unstructured":"Kim SB, Sayeed A, Villalon AH, et al. Safety analysis of adjuvant chemotherapy with docetaxel administered with or without anthracyclines to early stage breast cancer patients: combined results from the Asia-Pacific breast initiatives I and II. Asian Pac J Cancer Prev. 2016;17(2):697\u2013702.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"841_CR40","doi-asserted-by":"publisher","first-page":"356","DOI":"10.4048\/jbc.2015.18.4.356","volume":"18","author":"SB Kim","year":"2015","unstructured":"Kim SB, Kok YT, Thuan TV, Chao TY, Shen ZZ. safety results of Docetaxel-(Taxotere(R))-based chemotherapy in early breast cancer patients of Asia-Pacific region: Asia-Pacific Breast Initiative II. J Breast Cancer. 2015;18(4):356\u201364. \n                    https:\/\/doi.org\/10.4048\/jbc.2015.18.4.356\n                    \n                  .","journal-title":"J Breast Cancer."},{"issue":"29","key":"841_CR41","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/jco.2010.28.5437","volume":"29","author":"W Eiermann","year":"2011","unstructured":"Eiermann W, Pienkowski T, Crown J, et al. Phase III study of doxorubicin\/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011;29(29):3877\u201384. \n                    https:\/\/doi.org\/10.1200\/jco.2010.28.5437\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"9","key":"841_CR42","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/jco.2010.29.7689","volume":"29","author":"PA Ganz","year":"2011","unstructured":"Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011;29(9):1110\u20136. \n                    https:\/\/doi.org\/10.1200\/jco.2010.29.7689\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"2","key":"841_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1200\/jop.2015.004747","volume":"12","author":"Byfield S DaCosta","year":"2016","unstructured":"DaCosta Byfield S, Buck PO, Blauer-Peterson C, et al. ReCAP: treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the united states: a real-world retrospective study. J Oncol Pract. 2016;12(2):159\u201367. \n                    https:\/\/doi.org\/10.1200\/jop.2015.004747\n                    \n                  .","journal-title":"J Oncol Pract"},{"issue":"16","key":"841_CR44","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/nejmoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372. \n                    https:\/\/doi.org\/10.1056\/nejmoa052306\n                    \n                  .","journal-title":"N Engl J Med."},{"issue":"16","key":"841_CR45","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/nejmoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673\u201384. \n                    https:\/\/doi.org\/10.1056\/nejmoa052122\n                    \n                  .","journal-title":"N Engl J Med."},{"issue":"14","key":"841_CR46","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/nejmoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383. \n                    https:\/\/doi.org\/10.1056\/nejmoa0910383\n                    \n                  .","journal-title":"N Engl J Med."},{"issue":"7","key":"841_CR47","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/s1470-2045(13)70567-9","volume":"15","author":"L Fan","year":"2014","unstructured":"Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279\u201389. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(13)70567-9\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"2","key":"841_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/ajco.12454","volume":"12","author":"SB Kim","year":"2016","unstructured":"Kim SB, Sayeed A, Villalon AH, et al. Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: results from 5\u00a0years follow-up on Asia-Pacific Breast Initiative-I. Asia Pac J Clin Oncol. 2016;12(2):125\u201332. \n                    https:\/\/doi.org\/10.1111\/ajco.12454\n                    \n                  .","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"841_CR49","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/annonc\/mdl135","volume":"17","author":"M Martin","year":"2006","unstructured":"Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006;17(8):1205\u201312. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdl135\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"841_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.breast.2015.11.007","volume":"25","author":"J Maenpaa","year":"2016","unstructured":"Maenpaa J, Varthalitis I, Erdkamp F, et al. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer\u2013further observations from the IMPACT solid study. Breast (Edinburgh, Scotland). 2016;25:27\u201333. \n                    https:\/\/doi.org\/10.1016\/j.breast.2015.11.007\n                    \n                  .","journal-title":"Breast (Edinburgh, Scotland)."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0841-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0841-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0841-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:03:59Z","timestamp":1575313439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0841-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0841-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"11 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}